[go: up one dir, main page]

NO20055367L - Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst - Google Patents

Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Info

Publication number
NO20055367L
NO20055367L NO20055367A NO20055367A NO20055367L NO 20055367 L NO20055367 L NO 20055367L NO 20055367 A NO20055367 A NO 20055367A NO 20055367 A NO20055367 A NO 20055367A NO 20055367 L NO20055367 L NO 20055367L
Authority
NO
Norway
Prior art keywords
phenyl
methyl
combinations
anxiety
piperazine
Prior art date
Application number
NO20055367A
Other languages
English (en)
Inventor
Mauro Corsi
Sergio Melotto
Renzo Carletti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055367L publication Critical patent/NO20055367L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forehggende oppfirmelse angår terapeutiske kombinasjoner som irmbefatter paroksetin eller fysiologisk akseptable salter eller solvater derav og 2-(S)-(4-fluor-2-metyIfenyl)-piperazin-l-karboksylsyre [1-(R)- (3,5-bis-trifluormetyl-fenyl)-etyl]-metyl-amid eller fysiologisk akseptable salter eller solvater derav, farmasøytiske sammensetninger som irmeholder nevnte kombinasjoner og deres anvendelse ved behandling av depresjon og/eller angst.
NO20055367A 2003-04-17 2005-11-14 Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst NO20055367L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004126 WO2004091624A1 (en) 2003-04-17 2004-04-16 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety

Publications (1)

Publication Number Publication Date
NO20055367L true NO20055367L (no) 2005-11-14

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055368A NO20055368L (no) 2003-04-17 2005-11-14 Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
NO20055367A NO20055367L (no) 2003-04-17 2005-11-14 Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20055368A NO20055368L (no) 2003-04-17 2005-11-14 Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst

Country Status (18)

Country Link
US (4) US20060241143A1 (no)
EP (4) EP1615641A1 (no)
JP (4) JP2006523649A (no)
KR (2) KR20060003876A (no)
CN (2) CN1809355A (no)
AU (2) AU2004229179A1 (no)
BR (2) BRPI0409377A (no)
CA (2) CA2522313A1 (no)
CO (1) CO5700753A2 (no)
GB (1) GB0308968D0 (no)
IS (2) IS8128A (no)
MA (2) MA27731A1 (no)
MX (2) MXPA05011064A (no)
NO (2) NO20055368L (no)
PL (2) PL377858A1 (no)
RU (2) RU2005135647A (no)
WO (4) WO2004091616A1 (no)
ZA (2) ZA200508068B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998047514A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
IL150033A0 (en) * 1999-12-17 2002-12-01 Schering Corp Selective neurokinin antagonists
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
ES2291538T3 (es) * 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20060241143A1 (en) 2006-10-26
ZA200508068B (en) 2007-02-28
RU2005135649A (ru) 2006-03-20
WO2004091615A1 (en) 2004-10-28
EP1653956A1 (en) 2006-05-10
KR20060003875A (ko) 2006-01-11
KR20060003876A (ko) 2006-01-11
EP1615642A1 (en) 2006-01-18
MXPA05011064A (es) 2006-04-18
JP2006523650A (ja) 2006-10-19
CO5700753A2 (es) 2006-11-30
US20060241124A1 (en) 2006-10-26
MA27731A1 (fr) 2006-01-02
RU2005135647A (ru) 2006-06-10
AU2004229179A1 (en) 2004-10-28
CN1809359A (zh) 2006-07-26
WO2004091616A1 (en) 2004-10-28
CN1809355A (zh) 2006-07-26
JP2006523649A (ja) 2006-10-19
IS8128A (is) 2005-11-15
IS8129A (is) 2005-11-15
PL377857A1 (pl) 2006-02-20
MXPA05011063A (es) 2005-12-12
GB0308968D0 (en) 2003-05-28
US20060217395A1 (en) 2006-09-28
WO2004091617A1 (en) 2004-10-28
CA2522311A1 (en) 2004-10-28
AU2004229181A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
BRPI0409377A (pt) 2006-04-25
BRPI0409379A (pt) 2006-04-25
NO20055368L (no) 2005-11-14
CA2522313A1 (en) 2004-10-28
EP1615641A1 (en) 2006-01-18
EP1613325A1 (en) 2006-01-11
WO2004091624A1 (en) 2004-10-28
PL377858A1 (pl) 2006-02-20
JP2006523652A (ja) 2006-10-19
US20060287325A1 (en) 2006-12-21
MA27730A1 (fr) 2006-01-02
JP2006523651A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
JP2005532372A5 (no)
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
NO20161634A1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
UA100364C2 (xx) Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
EP1878725A3 (en) Pyrimidine derivatives and their use as CB2 modulators
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
NO20055367L (no) Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0215703B8 (pt) polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
NO20091969L (no) N-(2-hydroksyetyl)-N-metyl-4-(quinolin-8-yl(1-(tiazol-4-ylmetyl)piperidin-4-yliden)metyl)benzamid, fremgangsmate for fremstilling av den sa vel som dens anvendelse for behandling av smerte, angst og depresjon
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
DE60322064D1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
NO20054662L (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
AU2002333536A1 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
EP2308837A3 (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application